Blood Panel

Shujie Wang et al. (2022) · Gut microbes

This randomized trial with 365 adults who had newly diagnosed type 2 diabetes explored whether combining berberine, a plant compound extracted from the Chinese herb Coptis chinensis (Huanglian), with a probiotic mix lowers postprandial lipidemia, the rise in blood fats and cholesterol after a meal. The authors note that cholesterol measured after eating is also an important heart-disease risk marker, that after-meal blood fats are common in diabetes, and that very few treatments target them. Berberine was already known to lower fasting cholesterol, but whether it helps after meals was unknown. Probiotics are live bacteria, and the nine-strain mix here included Bifidobacterium breve. This analysis came from a 12-week, double-blind, placebo-controlled trial at 20 centers in China, with 365 participants split into four groups: placebo (91), probiotics alone (92), berberine alone (84), and both (98). Participants were drug-naive adults aged 20 to 70, averaging about 52. They took berberine pills twice daily before meals, and probiotic powder once daily at bedtime. After a standard 100 g carbohydrate meal, blood drawn 120 minutes later measured cholesterol and triglycerides, and stool samples tracked gut bacteria. Only the combination significantly cut after-meal total cholesterol (24.29 mg/dL drop versus 8.66 with placebo, adjusted P = .001, a gap that chance is very unlikely to explain) and after-meal LDL cholesterol (16.54 versus 7.35 mg/dL, P = .043). Berberine alone and probiotics alone did not differ significantly from placebo for these two measures. After-meal triglycerides fell with berberine alone (P = .037) and the combination (P = .035) equally, so probiotics added nothing there, and HDL (good) cholesterol did not differ between groups. Thirty-one blood lipid molecules changed only with the combination, versus eight with berberine and two with probiotics. In stool, B. breve rose with the combination, and higher levels went with lower after-meal cholesterol. In lab dishes, berberine slowed B. breve growth but switched on its fatty-acid-uptake genes (called fadD). Adverse events were not reported in this paper. The authors conclude that berberine plus probiotics acts synergistically on after-meal blood fats, with the probiotic replacing Bifidobacteria that berberine suppresses and berberine activating the bacteria's fat-handling genes. They state the limits plainly: only 13 weeks and no heart-attack or stroke outcomes, testing only after a carbohydrate meal, and unknown applicability to people already on statins. The authors propose that probiotics containing Bifidobacterium may be needed when berberine is used as a lipid-lowering agent. They suggest studying fatty meals and other gut-related pathways in future work.

Teresa Vezza et al. (2024) · Nutrients

This randomized trial with 66 healthy volunteers explored whether a daily capsule combining garlic powder and a concentrated onion extract lowers LDL cholesterol, the "bad" cholesterol that builds up in artery walls and drives heart and blood vessel disease. Medicines such as statins are usually kept for people with clearly raised LDL cholesterol or several risk factors, so people with slight elevations are generally pointed toward diet and lifestyle changes. Garlic and onion contain organosulfur compounds (sulfur-rich plant chemicals), which the authors say are linked to cholesterol-lowering, antioxidant and anti-inflammatory effects. To the authors' knowledge, human research had mostly looked at garlic alone, and none had combined the two plants in one capsule. Volunteers living in Granada, Spain, with LDL cholesterol between 100 and 190 mg/dL were split at random into two groups of 33. One group took a capsule called Aliocare daily with lunch, holding 86 mg of onion extract and 14 mg of garlic powder, and the other took an identical-looking placebo of plain cellulose. Neither participants nor researchers knew who received which. Blood samples and blood pressure were checked at the start and after 2, 4 and 8 weeks, including markers of oxidation and inflammation, liver and kidney function. After 8 weeks, LDL cholesterol was 6% lower in the capsule group (4% lower at 4 weeks), and total cholesterol about 6% lower. Among those starting above 110 mg/dL, LDL cholesterol dropped 12% by week 8. Triglycerides (blood fats) also fell, while good HDL cholesterol stayed unchanged and glucose did not differ. Oxidized LDL, a form of LDL damaged by oxidation and linked to artery disease, fell about 32% by week 8. Blood pressure was about 5% lower, and no adverse events were reported, with liver and kidney tests staying in the normal range. Compliance exceeded 95%, and participants did not guess their group assignment. Interleukin-6, an inflammation marker, tended to fall with the capsule without reaching significance, and malondialdehyde, another oxidation marker, did not differ. The authors conclude the capsule was safe and improved several heart-related measures, and they suggest garlic and onion may act together, though the study did not test each plant separately. They state plainly that the volunteers were mostly young with LDL cholesterol at the low end of the range, the pandemic limited recruitment, the sample was small and the 8-week duration short. The authors add that recruiting under different conditions would likely have produced higher baseline values and more robust results. They plan larger, longer studies in people with higher LDL cholesterol.

Dongho Shin et al. (2023) · The world journal of men's health

This randomized, double-blind, placebo-controlled trial with 80 men explored whether Maca (Lepidium meyenii), a root vegetable traditionally grown high in the Peruvian Andes and eaten as a nutritional "superfood," can ease late-onset hypogonadism (LOH), the cluster of low-testosterone-type symptoms, such as fatigue, low mood, reduced libido, and erectile difficulty, that many men develop with age even when their blood testosterone level is technically normal. Because standard testosterone replacement therapy carries cardiovascular and prostate-cancer risks, researchers wanted to know whether Maca, long used as a folk aphrodisiac and fertility aid, could offer relief without those risks. Eighty men over 40, recruited as outpatients at two South Korean hospitals and randomly split into two groups, took either 1,000 mg Maca tablets or an identical-looking placebo, two tablets three times a day before meals (about 5 grams of Maca daily), for 12 weeks. Neither the men nor the study staff knew who was getting the real supplement. Researchers tracked symptoms with four standard questionnaires covering overall aging-male symptoms, androgen deficiency, erectile function, and urinary symptoms, and ran blood tests for testosterone, cholesterol, and other safety markers at baseline, 4 weeks, and 12 weeks. Only the Maca group showed real improvement: overall symptom scores dropped by nearly 11 points from baseline (p<0.0001), while placebo barely moved (statistically unchanged, p=0.5007), and the difference between groups was highly significant (p<0.0001). Androgen-deficiency screening flipped from mostly positive to mostly negative in the Maca group (70.7% down to 56.1% at 12 weeks, p<0.0001 versus placebo). Erectile function scores rose by 14 points with Maca (p<0.0001, meaning a clear improvement) while the placebo group's scores actually fell, and urinary symptom scores improved with Maca too (p=0.0025) with no such change on placebo. Notably, none of this tracked with testosterone levels, which barely budged in either group, suggesting Maca works through some other pathway the study did not pin down. Only two participants reported mild stomach upset, and no serious safety issues turned up in blood work or vital signs. In men who were not candidates for testosterone therapy, this study found Maca well tolerated, with its effects on sexual and urinary symptoms rather than on lab-measured testosterone itself. The trial ran only 12 weeks, so it cannot say whether benefits last, and every participant was Korean, so results may not generalize to other populations. The researchers themselves flag that the biological mechanism behind Maca's effect is still unknown and call for longer, more mechanistic follow-up studies.

Metha Yaikwawong et al. (2024) · Nutrition journal

This 12-month randomized, double-blind, placebo-controlled trial with 272 adults with type 2 diabetes (T2DM) and obesity explored whether curcumin, the active compound in turmeric (Curcuma longa), could protect the pancreatic beta cells that produce insulin. In T2DM, obesity drives insulin resistance (cells responding poorly to insulin), which forces beta cells to work harder until their function starts to decline. Researchers tracked beta-cell function using HOMA-beta, an index calculated from fasting insulin and glucose, alongside HOMA-IR (a related index for insulin resistance) and two hormones made by fat tissue: adiponectin, which improves insulin sensitivity, and leptin, which signals fullness but runs high with excess body fat. Participants, all 35 or older and already taking metformin, were randomly assigned to six capsules a day (1,500 mg total) of standardized curcumin extract or an identical-looking placebo for 12 months, with 115 people in the placebo group and 114 in the curcumin group at randomization. Neither participants nor staff knew who received which capsule. Blood was drawn at baseline and every three months to measure fasting glucose, HbA1c (average blood sugar over about three months), body weight, BMI, insulin, HOMA-beta, HOMA-IR, adiponectin, and leptin. By 12 months, curcumin-treated participants had notably better beta-cell function than the placebo group (HOMA-beta 136.2 vs. 105.2; P<0.01, meaning their beta cells were working more efficiently), a difference that only became significant at 9 and 12 months, suggesting the benefit builds gradually rather than appearing right away. Insulin resistance dropped further with curcumin (HOMA-IR 4.86 vs. 6.04; P<0.001, lower is better), and blood sugar control improved (fasting glucose 115 vs. 131 mg/dL, P<0.05; HbA1c 6.12% vs. 6.47%, P<0.05). The curcumin group also lost more weight (66.1 vs. 69.3 kg, P<0.001) and lowered BMI (25.98 vs. 27.34, P<0.001), while adiponectin rose (14.5 vs. 10.4 ug/mL, P<0.001, more of the "good" fat hormone) and leptin fell (9.4 vs. 20.7 ug/mL, P<0.001, less of the fullness hormone that runs high in obesity). The authors connect these changes to curcumin's anti-inflammatory activity, since inflammation is a known driver of beta-cell decline. Mild side effects, abdominal pain, diarrhea, and headache, occurred in both groups with no one dropping out because of them, and liver and kidney markers stayed normal, suggesting curcumin extract is reasonably safe as a year-long add-on for people already managing T2DM with metformin. Because the trial tested only one dose at a single Thai hospital, it cannot show whether a different dose would work better or whether these results generalize elsewhere. Larger, multi-center trials testing a range of doses would help confirm curcumin's place alongside standard diabetes care.

Liuting Zeng et al. (2022) · Frontiers in immunology

This systematic review and meta-analysis pooled 31 randomized controlled trials (34 study records, roughly 1,583 participants) exploring curcumin and Curcuma longa (turmeric) extract across 10 autoimmune diseases — conditions where the immune system mistakenly attacks the body's own tissue. Autoimmune disease covers more than 120 named conditions; this review focused on ankylosing spondylitis, Behçet's disease, Crohn's disease, multiple sclerosis, oral lichen planus, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, Takayasu arteritis, and ulcerative colitis. Curcumin is the main active compound in turmeric, long used in Chinese medicine, and is studied here for its ability to regulate immune cells and reduce inflammation. Researchers searched English and Chinese databases plus the Cochrane Library and ClinicalTrials.gov through February 2022, screening 2,991 records down to 31 RCTs that tested curcumin or Curcuma longa extract against placebo or usual care. Trial count per disease varied widely: 9 RCTs for ulcerative colitis and 6 for oral lichen planus, but only 1 each for ankylosing spondylitis, Behçet's disease, and Takayasu arteritis. Doses ranged from 60 mg to 6,000 mg daily, taken orally, or in some trials applied as a gel, mouthwash, or enema, for 2 to 96 weeks. Disease activity was tracked with condition-specific scales (PASI for psoriasis, DAS28 for rheumatoid arthritis, EDSS for multiple sclerosis, and others) alongside blood markers like ESR and CRP. Where enough trials existed to combine statistically, curcumin performed well. In psoriasis, it roughly tripled the rate of major skin-clearance (PASI75: RR=3.01, p=0.008—meaning patients getting curcumin were about three times as likely to see substantial improvement). In ulcerative colitis, it raised clinical remission more than twofold (RR=2.28, p=0.0005) and lowered inflammatory markers ESR and CRP. In rheumatoid arthritis, it reduced the DAS28 disease-activity score (WMD=-1.10, p=0.0002—a clinically noticeable drop in joint disease activity), though results varied considerably between the five trials. Oral lichen planus, despite being studied in six trials, did not show a significant benefit on its pooled lesion-severity score (p=0.17). None of the pooled analyses found more side effects with curcumin than with placebo. The other six diseases each had just one or two small trials reporting improvement, too few to combine or confirm. These findings support curcumin as a reasonably safe adjunct for psoriasis, ulcerative colitis, and rheumatoid arthritis specifically, where the evidence is strongest and most consistent; for the seven other diseases, results are preliminary and should not yet guide treatment decisions. Curcumin's poor absorption from the gut remains a practical obstacle to reliable dosing. The authors call for larger, multi-center trials, especially for the thinly studied conditions, before broader clinical recommendations can be made.

Rodsarin Yamprasert et al. (2020) · BMC complementary medicine and therapies

This randomized, double-blind, controlled trial with 80 adults (ages 18-70, about 70% female) compared ginger (Zingiber officinale) extract against loratadine, a standard non-drowsy antihistamine, for allergic rhinitis (AR) -- an immune reaction to airborne allergens that causes nasal itching, congestion, runny nose, and sneezing, affecting an estimated 400 million people worldwide. Ginger is a spice long used in Thai traditional medicine, and its active compounds 6-gingerol and 6-shogaol have shown anti-allergic activity in lab studies by blocking mast cells, the immune cells that release histamine during an allergic reaction. Antihistamines like loratadine work well but can cause drowsiness and dry mouth. Participants with moderate AR symptoms took either 500 mg of standardized ginger extract or 10 mg of loratadine daily, in identical-looking capsules, for 6 weeks. Researchers tracked nasal symptoms using the Total Nasal Symptom Score (TNSS, rating itching, runny nose, congestion, and sneezing on a 0-12 scale), objectively measured nasal airway size with acoustic rhinometry (a sound-wave-based nasal scan), and assessed quality of life with the 28-item Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Blood tests and blood pressure checks monitored safety at baseline, week 3, and week 6. Both treatments significantly reduced nasal symptom scores by week 6 (ginger: 7.48 to 3.42; loratadine: 7.38 to 4.11), with no statistically significant difference between them (p=0.276--meaning both worked about equally well). On the nasal airway scan, ginger significantly increased left-nostril airway volume compared to loratadine by week 6 (+0.094 cm3 vs -0.006 cm3, p=0.02--meaning ginger measurably relieved congestion where loratadine did not). Quality-of-life scores improved similarly in both groups across all seven RQLQ domains (p=0.660 at week 6). Side effects differed in kind more than in severity: ginger caused more digestive upset (eructation, or burping, in 72% vs 17% on loratadine), while loratadine caused more drowsiness (25% vs 3%), dizziness, and constipation. Neither treatment affected blood pressure or kidney function; loratadine modestly raised a liver enzyme (ALP) that ginger did not. These results suggest ginger extract works about as well as loratadine for relieving AR symptoms and improving quality of life, with a milder side-effect profile centered on digestion rather than sedation. The trial was short (6 weeks), single-site, and modestly sized (80 enrolled, 72 completing), so larger and longer studies are needed to confirm both the congestion benefit and long-term safety, including the loratadine-associated liver-enzyme signal seen here.